RECORD // Company

Harmony Biosciences Holdings, Inc.

Built 2026-11-21T00:27:31Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001104659-26-122390

ItemValuePeriodFormFiledAccessionReport
Revenue$268,917,0003 months ended 2026-09-3010-Q2026-11-040001104659-26-1223902026-11-21 00:27 UTCReport an error
Net income (loss)$48,196,0003 months ended 2026-09-3010-Q2026-11-040001104659-26-1223902026-11-21 00:27 UTCReport an error
Interest expense$3,060,0003 months ended 2026-09-3010-Q2026-11-040001104659-26-1223902026-11-21 00:27 UTCReport an error
Cash and cash equivalents$647,099,000at 2026-09-3010-Q2026-11-040001104659-26-1223902026-11-21 00:27 UTCReport an error
Debt due in the next 12 months$20,000,000at 2026-09-3010-Q2026-11-040001104659-26-1223902026-11-21 00:27 UTCReport an error
Debt due in year 2$125,000,000at 2026-09-3010-Q2026-11-040001104659-26-1223902026-11-21 00:27 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001802665
Ticker
HRMY
EIN
822279923
CUSIP
413197104
Record ID
sx:sec:0001802665

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 00:27 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 00:27 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 00:27 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 00:27 UTCReport an error
Business address630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING, PA, 194622026-11-16SEC EDGAR company profile2026-11-21 00:27 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 00:27 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$868,453,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 00:27 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$158,687,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 00:27 UTCReport an error
Total assets (at 2025-12-31)$1,271,631,0002025-12-3110-K, XBRL Assets2026-11-21 00:27 UTCReport an error
Stockholders' equity (at 2025-12-31)$870,218,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 00:27 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$752,502,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 00:27 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$348,199,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 00:27 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$310,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 00:27 UTCReport an error
Long-term debt (at 2025-12-31)$163,663,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 00:27 UTCReport an error
Operating lease liabilities (at 2025-12-31)$5,585,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 00:27 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.2026-11-04SEC EDGAR 8-K 0001104659-26-122377 (text as filed, excerpt)2026-11-21 00:27 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)On November 4, 2026, the Company posted an investor presentation to its website at ttps://ir.harmonybiosciences.com (the “Investor Presentation”). A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the…2026-11-04SEC EDGAR 8-K 0001104659-26-122377 (text as filed, excerpt)2026-11-21 00:27 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-13)On October 12, 2026, the Company issued a press release announcing the leadership transition described in Item 5.02 of this Current Report. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as set forth…2026-10-13SEC EDGAR 8-K 0001104659-26-115282 (text as filed, excerpt)2026-11-21 00:27 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-04)On August 4, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.2026-08-04SEC EDGAR 8-K 0001104659-26-090086 (text as filed, excerpt)2026-11-21 00:27 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-04)On August 4, 2026, the Company posted an investor presentation to its website at ttps://ir.harmonybiosciences.com (the “Investor Presentation”). A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the…2026-08-04SEC EDGAR 8-K 0001104659-26-090086 (text as filed, excerpt)2026-11-21 00:27 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$258,582,5452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #2 (13F as filed): FMR LLC$130,133,5202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$104,878,6042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #4 (13F as filed): AMERICAN CENTURY COMPANIES INC$92,463,6322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #5 (13F as filed): DIMENSIONAL FUND ADVISORS LP$87,144,8172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$76,644,9802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #7 (13F as filed): STATE STREET CORP$67,697,9142026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #8 (13F as filed): ARMISTICE CAPITAL, LLC$56,945,2402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$52,534,4762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error
Largest institutional holder #10 (13F as filed): ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$47,789,9462026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 00:27 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.